Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes
Launched by UNIVERSITY OF COLORADO, DENVER · Feb 29, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how hormonal changes during the menstrual cycle affect blood sugar levels in women with type 1 diabetes. Researchers want to understand how factors like hormonal birth control and different phases of the menstrual cycle influence both high and low blood sugar (hyperglycemia and hypoglycemia) and how exercise impacts these responses. The goal is to find ways to adjust insulin doses and food intake to help manage blood sugar levels better during these times.
To participate in this study, women aged 18 to 45 who have been diagnosed with type 1 diabetes for at least a year can apply, as long as they are still having menstrual cycles or are using birth control pills. Unfortunately, women who are postmenopausal, pregnant, or have had a hysterectomy cannot join. Those who take part can expect to share their experiences related to their menstrual cycle and how it affects their diabetes management, and they will receive support in making adjustments to improve their health outcomes.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women 18-45 who have had type 1 diabetes for at least 12 months
- • Premenopausal with either menstrual cycles or currently using oral contraceptives
- Exclusion Criteria:
- • Women who are postmenopausal, pregnant, trying to become pregnant, or have had a hysterectomy
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
JANET K SNELL-BERGEON, PhD, MPH
Principal Investigator
University of Colorado, Denver
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported